



DAY 1: Wednesday, 20 May 2026

8:30 AM Welcome Coffee

9:00 AM Official Opening

Session 1: Long-Acting Platforms

9:05 AM Innovative Modalities for Delivering Long-Acting Antivirals
[Andrew Owen](#)
University of Liverpool, United Kingdom

9:25 AM GS-1179 and GS-5366: Long-Acting Oral Helicase-Primase Inhibitors for the Treatment of Recurrent Genital Herpes
[Alexandre Mercier](#)
Gilead Sciences, Inc., United States

9:40 AM Advancing Long-Acting Injectables with BEPO® in Situ Forming Depot Technology
[Sylvestre Grizot](#)
Medincell, France

9:55 AM NIH DART Center for Ultra-Long-Acting Antiretroviral Release Technologies
[Alessandro Gattoni](#)
Center for BioNanoengineering, Houston Methodist Hospital, Houston, Texas, United States

10:10 AM Long-Acting Injectable Classification: A System to Guide Product Design, Development, Approval and Market Scaling
[Rodney Ho](#)
University of Washington, Washington DC, United States

10:20 AM Q&A and Discussion

10:35 AM Coffee Break

Session 2: Long-Acting Approaches for Prevention

11:05 AM User Preferences and Considerations in Designing Prevention Strategies
[José A. Bauermeister](#)
University of Pennsylvania, United States

11:25 AM Treatment of HBV as Prevention of Liver Cancer
[Chari A. Cohen](#)
Hepatitis B Foundation, Baruch S. Blumberg Institute, United States

Abstract-Driven presentations:

11:45 AM #1 PrEP-Naive Lenacapavir Initiators More Likely to Be Assigned Female Sex at Birth in a Real-World Cohort
Meredith E. Clement

11:55 AM #3 Adherence to Oral Versus Long-Acting Injectable HIV Preexposure Prophylaxis among Women Who Inject Drugs
Douglas Krakower

12:05 PM #4 Early Patient-Reported Outcomes and Planned Persistence with Lenacapavir for HIV Pre-Exposure Prophylaxis in Routine Clinical Care
Aniruddha Hazra

12:15 PM #2 The Use of PBPK Modelling to Assess the Need for Simultaneous Oral Initiation with Long-Acting Cabotegravir and Rilpivirine in the Setting of Post-exposure Prophylaxis (PEP).
Doaa Ahmed Mohamed

12:25 PM Q&A and Discussion



12:45 PM Lunch

Session 3: Long-Acting Therapeutics Beyond HIV

1:45 PM Update on the Use of Long-Acting Monoclonal Antibodies for Malaria Prevention
[Kirsten E. Lyke](#)
 Center for Vaccine Development and Global Health, United States

2:05 PM Long-Acting for Hepatitis C: Treatment and Cure
[David L. Thomas](#)
 Johns Hopkins School of Medicine, Baltimore, United States

2:25 PM A Shot at Better Adherence: Integrating Long-Acting Injectable Therapies for Tuberculosis
[Todd Black](#)
 TB Alliance, New York, United States

Abstract-Driven presentations:

2:40 PM #5 Long-Acting Injectable Treatment for Tuberculosis: Multi-Country Cross-Sectional Study to Examine Preferences, Acceptability, and Trade-Offs
 Christopher Vinnard

2:50 PM #6 A Regulatory Strategy for Long-Acting Injectable Regimens for Tuberculosis
 Liz Daghish

3:00 PM Q&A and Discussion

3:15 PM Coffee Break & Poster Viewing

Session 4: Therapeutic Considerations using LA-ARVs in Key Populations

3:45 PM Behavioral Considerations and Adherence Strategies for People Who Use Drugs
[Sunil Solomon](#)
 Johns Hopkins University, United States

4:05 PM Use of CAB/RPV in Pregnancy: Ready for Prime Time?
[William R. Short](#)
 University of Pennsylvania, United States

Abstract - Driven presentations:

4:25 PM #7 Clinician Attitudes Toward and Utilization of Long-Acting Injectable Cabotegravir/Rilpivirine for Pregnant Persons Living With HIV
 Owen Parra

4:35 PM #8 PREFER-LA: Improved Adherence and Viral Control in Real-World Study of People With HIV in the United States With Adherence Challenges on Oral Antiretroviral Therapy
 Elizabeth Moore

4:45 PM #9 Rethinking Eligibility: Long-Acting Cabotegravir/Rilpivirine Achieves Suppression in Viremic Individuals: From the Midway Cohort
 Jennifer Kuretski

4:55 PM Q&A and Discussion

5:15 PM End of Day 1

7:00 PM Networking Dinner



DAY 2: Thursday, 21 May 2026

Session 5: Long-Acting Antiretrovirals - Resistance

- 09:00 AM Development of Resistance to bNABs
[Katharine Bar](#)
Perelman School of Medicine, University of Pennsylvania, United States
- 09:20 AM Resistance Globally and Its Impact on the Use of Long-Acting Antiretrovirals
[Michael Jordan](#)
Tufts University and Tufts Medical Center, Boston, MA, USA
- Abstract-Driven presentations:**
- 09:40 AM #10 How Long-Acting Anti-Infective mAbs Can Catalyze Global mAb Pharmacoequity
Huub Gelderblom
- 09:50 AM #12 ACC085, a Novel HIV-1 Capsid Function Inhibitor, Exhibits Human Pharmacokinetics Predicted from Nonclinical Data Using a PBPK Model, Supporting Its Long-Acting Potential in Humans
Qin Hong

10:00 AM Q&A and Discussion

10:20 AM Coffee Break & Poster Viewing

Session 6: Challenges and strategies to managing LA Therapies

- Abstract-Driven presentations:**
- 10:50 AM #13 Leveraging Pharmacists and Pharmacy Technicians to Optimize Long-Acting Injectable Antiretroviral Therapy Access, Adherence, and Clinical Outcomes
Katerina Christopoulos
- 11:00 AM #14 On-time Injection Adherence and Persistence among People with HIV on Long-Acting Cabotegravir/Rilpivirine
Yotam Arens
- 11:10 AM Management of Low-Level Viremia among People Who Have Already Been Started on Long-Acting ART
[Ethel D. Weld](#)
Johns Hopkins University School of Medicine, Baltimore, United States
- 11:30 AM Panel Discussion

Session 7: Long-Acting Anti-Infectives: What will the future hold?

- 12:00 PM Beyond Passive Infusion: Nucleic Acid Delivery of Long-Acting Monoclonal Antibodies
[Pablo Tebas](#)
University of Pennsylvania, United States
- Abstract-Driven presentations:**
- 12:20 PM #15 In-Country Evaluation of Compact Prefilled Autodisable Devices for Delivery of Long-Acting Medicines in Uganda and Zambia
Sarah Sterner
- 12:30 PM #16 A Novel Islatravir Prodrug Formulated as a Long-Acting Nanosuspension for HIV Treatment
Sijia Tao
- 12:40 PM #17 Pharmacokinetics and Evaluation of Potential Dosing Regimens for Long-Acting VH4524184
Hyunmoon Back



12:50 PM #18 Injectable HIV-1 Capsid Inhibitor VH4011499 (VH-499) Formulation Supports Twice-Yearly Dosing
Jose R. Castillo-Mancilla

1:00 PM Discussion

1:10 PM Closing Remarks

1:15 PM End of Program



Corporate support

PLATINUM SPONSOR



CONTRIBUTOR



NON-FINANCIAL SPONSOR



ENDORSERS

